Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals posts Q1 GAAP loss of $92.5 million; cuts 2025 profit guidance

Negative Impact 4 of 5 earnings Written later

Jazz reported first-quarter 2025 total revenues of $897.8 million, roughly flat with $902.0 million a year earlier, and a GAAP net loss of $92.5 million, or $1.52 per share, versus a $14.6 million loss in the prior-year quarter. The loss reflects a $172.0 million expense for Xyrem antitrust litigation settlements, and the company cut its 2025 profit guidance while affirming its revenue range of $4.15 billion to $4.40 billion.

Key points

  • Q1 2025 non-GAAP adjusted net income was $105.2 million, or $1.68 per diluted share, down from $178.4 million, or $2.63, in Q1 2024.
  • 2025 GAAP net loss guidance is now $(615) million to $(450) million, versus prior net income guidance of $560 million to $720 million.
  • 2025 non-GAAP adjusted net income guidance is now $250 million to $350 million, versus prior guidance of $1.4 billion to $1.5 billion.
  • The guidance change reflects the April 2025 Chimerix acquisition, which the company completed for approximately $935 million in cash.

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECMay 6, 2025, 4:08 PM ET
Accession number0001232524-25-000025

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.